The Form 4 filing, an SEC report of insider stock activity, was filed on November 16, 2026. It lists November 12, 2026, as both the earliest and latest transaction date.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-12 |
| Date of Latest Transaction | 2026-11-12 |
| Buy/Sell | sell |
| Transaction Count | 4 |
| Shares Transacted | 10,376 |
| Price | $169.76 |
| Total Transaction Value | $1,761,436.95 |
| Insider | |
| Ticker Symbol | GILD |
| Company | GILEAD SCIENCES, INC. |
| Insider Name | Kramer Kelly A. |
| Insider Title | Director |
| Sector - Industry | Healthcare - Drug Manufacturers - General |
| Holdings | |
| Total Shares Owned After Transaction | 1,339 |
| Position Size Change | 88.57% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of GILD shares, reported under transaction code S. Kelly A. Kramer, a Gilead Sciences director, reported four sale transactions. All four were included in one filing.
What was the average price of the transaction?
The average price was $169.76 per share across the four sales. Separate prices for each sale are not available in the transaction details here.
How did this transaction affect the insider's holdings?
The sales reduced the reported holdings by 10,376 shares, leaving 1,339 shares owned afterward. The amount sold was 88.57% of the reported shares held before the sales.
What's the total transaction value?
The total reported value was $1,761,436.95 for the four sales on November 12, 2026.
Are there any special circumstances around this transaction?
The transaction information identifies a Rule 10b5-1 trading-plan reference. These plans set trading instructions ahead of time. The filing footnotes and plan wording are not available here, so it is unclear whether the reference covers all four sales or only some. The plan's start date and trading terms are unknown. The reference alone does not confirm that the sales met the rule's requirements.
For research purposes only; not investment advice.